Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation

Yemisi Takwoingi,1 Hilary Whitworth,2,3 Melanie Rees-Roberts,2,4 Amarjit Badhan,2,4 Christopher Partlett,1 Nathan Green,5,6,7,8 Aime Boakye,2,4 Heather Lambie,2 Luigi Marongiu,2 Mark Jit,8,9 Peter White,5,6,7,8 Jonathan J Deeks,1 Onn Min Kon2,4,10 and Ajit Lalvani2,4* on behalf of the Interferon Gamma Release Assays for Diagnostic Evaluation of Active Tuberculosis (IDEA) study group†

1Institute of Applied Health Research, University of Birmingham, Birmingham, UK
2Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London, London, UK
3Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
4National Institute for Health Research (NIHR) Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK
5NIHR Health Protection Research Unit in Modelling Methodology, Imperial College London, London, UK
6Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling, Imperial College London, London, UK
7Department of Infectious Disease Epidemiology, Imperial College London, London, UK
8Modelling and Economics Unit, Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK
9Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
10St Mary’s Hospital, Imperial College Healthcare Trust, London, UK

*Corresponding author a.lalvani@imperial.ac.uk
†For a full list of IDEA study collaborators, please see Acknowledgements
Declared competing interests of authors: Ajit Lalvani is the named inventor for several patents underpinning T-cell-based diagnosis including interferon gamma, enzyme-linked immunospot assay, ESAT-6, CFP-10, Rv3615c, Rv3873 and Rv3879c. He has royalty entitlements from the University of Oxford spin-out company (Oxford Immunotec plc), in which he has held a minority share of equity and he is a member of the Efficacy and Mechanism Evaluation Board. Jonathan J Deeks is a member of the Health Technology Assessment (HTA) Commissioning Board and the HTA Efficient Study Designs Board. Onn Min Kon is chairperson of the UK Joint Tuberculosis Committee. Peter White has received research funding from Otsuka SA for a retrospective study of multidrug-resistant tuberculosis treatment in several eastern European countries outside the submitted work. He received grants from the Medical Research Council during the conduct of the study.

Published May 2019
DOI: 10.3310/hta23230

Plain English summary

Interferon gamma release assays for diagnosing active tuberculosis
Health Technology Assessment 2019; Vol. 23: No. 23
DOI: 10.3310/hta23230

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Tuberculosis (TB) is one of the world’s most important infectious diseases. In 2014, 1.5 million deaths were caused by the disease – about one death every 25 seconds. Traditional diagnosis of TB is based partly on the tuberculin skin test. Blood tests such as QuantiFERON GOLD In-Tube (QFT-GIT; Cellestis, Carnegie, VIC, Australia) and T-SPOT.TB® (Oxford Immunotec, Abingdon, UK) are now available. However, these two tests are not used as part of current NHS practice because of the lack of evidence about how well the tests perform when diagnosing symptomatic (active) TB in routine clinical practice.

The purpose of our study was to compare the ability of QFT-GIT and T-SPOT.TB to differentiate people with active TB from those without active TB in a population suspected of the disease. We also assessed new blood tests that are currently being developed for diagnosis of active TB.

We recruited 1074 patients with suspected TB from 14 NHS hospitals in London, Slough, Oxford, Leicester and Birmingham into our study. We found that T-SPOT.TB correctly detected more people with active TB than QFT-GIT; T-SPOT.TB would miss about 18 people out of every 100, whereas QFT-GIT would miss about 33 people out of every 100 with active TB.

For this reason, neither test is good enough for routine clinical use because the number of people with active TB who are incorrectly diagnosed as not having active TB is unacceptably high. In addition, neither test is good value for money. However, we did find that some of the newer blood tests performed better than T-SPOT.TB and their usefulness should be further investigated.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.513

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 08/106/02. The contractual start date was in March 2011. The draft report began editorial review in May 2016 and was accepted for publication in September 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Takwoingi et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).